Silence Therapeutics
SLN
28 hedge funds and large institutions have $277M invested in Silence Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 3 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
51% more capital invested
Capital invested by funds: $183M → $277M (+$93.7M)
0.06% more ownership
Funds ownership: 17.33% → 17.39% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less funds holding
Funds holding: 29 → 28 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
+$1.91M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$1.2M |
| 3 |
Morgan Stanley
New York
|
+$731K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$387K |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.36M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$692K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$273K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$226K |
| 5 |
SG Americas Securities
New York
|
-$144K |
SLN Hedge Fund Activity: Q4 2022 in Review
28 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2022, worth a combined $277M — up 51% from $183M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SLN and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 9 added.
The largest buyer was M28 Capital Management, opening a new position worth an estimated $1.91M. The largest seller was Point72 Asset Management, cutting an estimated $2.36M.
- 28 institutional investors held Silence Therapeutics (SLN) as of Q4 2022, down from 29 in Q3 2022.
- Funds reported $277M of Silence Therapeutics stock for Q4 2022, up 51% quarter-over-quarter.
- 2 funds opened new Silence Therapeutics positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Silence Therapeutics buyer in Q4 2022 was M28 Capital Management, an estimated $1.91M added.
- The largest Silence Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $2.36M sold.
Based on aggregated 13F filings for Q4 2022.